Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas
暂无分享,去创建一个
C. Antonescu | J. Coindre | A. Italiano | R. Maki | N. Sevenet | M. Breen | Rachael Thomas | M. Longy | F. Bonnet | Chun‐Liang Chen
[1] S. Voss,et al. Leukemia and lymphoma. , 2011, Radiologic clinics of North America.
[2] K. Lindblad-Toh,et al. Refining tumor-associated aneuploidy through ‘genomic recoding’ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas , 2011, Leukemia & lymphoma.
[3] Kecheng Zhang,et al. Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. , 2011, Histology and Histopathology.
[4] D. Stoppa-Lyonnet,et al. EMMA, a cost‐ and time‐effective diagnostic method for simultaneous detection of point mutations and large‐scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients , 2011, Human mutation.
[5] V. de Giorgi,et al. Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy , 2011, Histopathology.
[6] C. Antonescu,et al. Consistent MYC and FLT4 gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions , 2011, Genes, chromosomes & cancer.
[7] David M. Thomas,et al. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.
[8] F. Chibon,et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. , 2010, The American journal of pathology.
[9] M. Landthaler,et al. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. , 2010, Anticancer research.
[10] Derek Y. Chiang,et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.
[11] C. Harris,et al. Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.
[12] J. Hunt,et al. Allelic loss of 3 different tumor suppressor gene loci in benign and malignant endothelial tumors of the head and neck. , 2009, Archives of pathology & laboratory medicine.
[13] Narasimhan P. Agaram,et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. , 2009, Cancer research.
[14] L. Qin,et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Cordon-Cardo,et al. Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.
[16] K. Hunt,et al. Genetic aberrations in soft tissue leiomyosarcoma. , 2009, Cancer letters.
[17] Paul D. P. Pharoah,et al. p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.
[18] Gerald C. Chu,et al. P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.
[19] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[20] Zhou Xiaoyan,et al. Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[21] R. Mason,et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.
[22] P. Pandolfi,et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. , 2008, Genes & development.
[23] J. Blay,et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] D. Stoppa-Lyonnet,et al. High‐throughput simultaneous detection of point mutations and large‐scale rearrangements by CE , 2007, Electrophoresis.
[25] G. Tate,et al. Mutation of the PTEN gene in a human hepatic angiosarcoma. , 2007, Cancer genetics and cytogenetics.
[26] Dihua Yu,et al. High prevalence of p53 exon 4 mutations in soft tissue sarcoma , 2007, Cancer.
[27] P. Pandolfi,et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.
[28] F. Chibon,et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity , 2007, European Journal of Human Genetics.
[29] R. Maki,et al. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Tak W. Mak,et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.
[31] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[32] B. Gunawan,et al. Comparative genomic hybridization in four angiosarcomas of the female breast. , 2005, Gynecologic oncology.
[33] A. Balmain,et al. Genetic interactions between Pten and p53 in radiation-induced lymphoma development , 2003, Oncogene.
[34] M. Solé,et al. Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia , 2003, Modern Pathology.
[35] N. Wong,et al. Sinonasal angiosarcoma with marrow involvement at presentation mimicking malignant lymphoma: cytogenetic analysis using multiple techniques. , 2001, Cancer genetics and cytogenetics.
[36] Y. Zu,et al. Chromosomal Abnormalities and p53 Gene Mutation in a Cardiac Angiosarcoma , 2001, Applied immunohistochemistry & molecular morphology : AIMM.
[37] D. Wiederschain,et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. , 2000, The American journal of pathology.
[38] A. Zeiher,et al. Akt takes center stage in angiogenesis signaling. , 2000, Circulation research.
[39] P. Vogt,et al. The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] A. Sendelhofert,et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. , 1998, The American journal of pathology.
[41] L. Cerilli,et al. Primary renal angiosarcoma: a case report with immunohistochemical, ultrastructural, and cytogenetic features and review of the literature. , 1998, Archives of pathology & laboratory medicine.
[42] L. Cantley,et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.
[43] T. Ochi,et al. Mutations of p53 tumor‐suppressor gene in angiosarcoma , 1997, International journal of cancer.
[44] C. Cordon-Cardo,et al. Alterations of tumor suppressor genes in bladder cancer. , 1997, Seminars in diagnostic pathology.
[45] K. Ishak,et al. p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. , 1995, Carcinogenesis.
[46] A. Llombart‐Bosch,et al. Cytogenetic study of angiosarcoma of the breast , 1994, Genes, chromosomes & cancer.
[47] E. van den Berg,et al. Comparison of cytogenetic abnormalities and deoxyribonucleic acid ploidy of benign, borderline malignant, and different grades of malignant soft tissue tumors. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[48] F. Mitelman,et al. Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma , 1990, Genes, chromosomes & cancer.
[49] E. Freireich. Leukemia and lymphoma. , 1971, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.
[50] A. Marx,et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. , 2010, The American journal of pathology.
[51] L. Kindblom,et al. Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome , 2005, Virchows Archiv A.
[52] A. Tannapfel,et al. Mutation analysis of K‐ras‐2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride , 2002, Environmental and molecular mutagenesis.
[53] Y. Amo,et al. Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. , 2002, Acta dermato-venereologica.
[54] F. Mertens,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .
[55] Cdm Fletcher,et al. World Health Organization Classification of Tumours , 2002 .
[56] C. Harris,et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. , 1994, Carcinogenesis.